Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01790893
Study type Interventional
Source Retina Associates of Kentucky
Contact Diana Holcomb, COA
Phone 859-264-2905
Email dholcomb@retinaky.com
Status Recruiting
Phase Phase 1/Phase 2
Start date March 2013
Completion date August 2014

See also
  Status Clinical Trial Phase
Terminated NCT00272766 - Macugen for Histoplasmosis N/A